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Abstract
Prior studies have identified recurrent oncogenic mutations in colorectal adenocarcinoma1 and
have surveyed exons of protein-coding genes for mutations in 11 affected individuals2,3. Here we
report whole-genome sequencing from nine individuals with colorectal cancer, including primary
colorectal tumors and matched adjacent non-tumor tissues, at an average of 30.7× and 31.9×
coverage, respectively. We identify an average of 75 somatic rearrangements per tumor, including
complex networks of translocations between pairs of chromosomes. Eleven rearrangements
encode predicted in-frame fusion proteins, including a fusion of VTI1A and TCF7L2 found in 3
out of 97 colorectal cancers. Although TCF7L2 encodes TCF4, which cooperates with β-catenin4
in colorectal carcinogenesis5,6, the fusion lacks the TCF4 β-catenin–binding domain. We found a
colorectal carcinoma cell line harboring the fusion gene to be dependent on VTI1A-TCF7L2 for
anchorage-independent growth using RNA interference-mediated knockdown. This study shows
previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to
essential gene fusions and other oncogenic events.
Colorectal cancer has served as a model to understand the progressive acquisition of
oncogenic mutations in genes and pathways such as APC, CTNNB1, TP53, RAS genes and
TGF-β signaling1,7. Exome-wide sequencing has recently identified additional recurrent
mutations that may contribute to carcinogenesis2,3. Further, genomic studies of colorectal
cancer have detailed subgroups of tumors characterized by chromosomal instability (~60–
70%), or by a high degree of microsatellite instability, often associated with hereditary or
sporadic mismatch repair deficiency (~15%), with additional cases falling between these
classes7,8.
We sequenced the genomes of nine colorectal cancers and paired non-neoplastic tissue
controls (Table 1). Tumors were resected before administration of chemotherapy or
radiation and were selected for sequencing based upon a pathology-estimated purity of
>70%. We used SNP arrays to confirm tumor purity and inferred ploidy and to select
samples with copy-number alterations suggestive of a chromosomal-instability phenoytpe.
We whole-genome sequenced these samples with paired 101-base reads with an average of
30.7× sequence coverage of the tumor genomes and 31.9× coverage of the germline (Table
1). We were able to reliably call mutations at ~83% of bases (with a range of 78–87%) based
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on the ability to uniquely align sequence reads and obtain ≥14× coverage in the tumor and
≥8× coverage in the germline.
These cases revealed frequent alterations in both sequence and genomic structure. Using the
MuTect and Indelocator algorithms9–11, we called 137,968 candidate somatic mutations
across the nine samples. To evaluate our mutation calling, we validated candidate mutations
predicted to cause non-synonymous substitutions or insertions-deletions in protein-coding
sequences (Supplementary Tables 1 and 2). Among these 712 candidates, 521 could be
tested by mass spectrometric genotyping, and we validated 84% (439) as somatic alterations.
Notably, genotyping validation rates were ~95% (292 out of 308) for mutations at a high
allele fraction (>0.33). The higher validation rate for higher allele fraction mutations is
consistent with the possibility that mass spectrometric techniques require a minimum
threshold for variant allele detection.
The whole-genome sequence also allows us to evaluate the overall features of somatic
mutations. Using all candidate mutations, we calculated an overall mutation rate of ~5.9 per
Mb with a range of 4.0–9.8 mutations per Mb relative to a haploid genome (Table 1).
Assuming that as many as 16% of these events are false positives, this would predict a
mutation rate of ~5 mutations per Mb. This mutation rate exceeds the previously estimated
rate of 1.2 mutations per Mb derived from a sequencing tiling array3, likely reflecting the
greater sensitivity of massively parallel sequencing. The mutation rate is somewhat higher in
intergenic regions (6.7 per Mb) than in intronic and exonic sequences (4.8 per Mb and 4.2
per Mb, respectively), presumably because of selection pressure and transcription-coupled
repair12,13. Within coding sequences, the rate of non-synonymous mutations that we saw,
3.1 per Mb, resembles the 2.8 per Mb rate seen from Sanger resequencing2.
The base context of the somatic mutations is consistent with previous reports that colorectal
cancers show a strong predilection for C>T transitions at CpG dinucleotides2,3; we found an
increase in mutations at CpG sites (37–72 per million sites) compared to all mutations other
than CpG transitions (3.2–8.5 per Mb) (Supplementary Fig. 1). Inspection of consensus loci
used to test for sporadic mismatch repair deficiency14 showed no signs of microsatellite
instability. We observed low rates of insertions-deletions within coding regions (0–5 events
per tumor).
Analysis of the non-synonymous coding somatic substitutions and small insertions-deletions
identified 24 genes with such mutations in two or more tumors (Supplementary Table 3).
Although the small sample set provides inadequate power to detect recurrent mutations,
KRAS, APC and TP53 nonetheless scored as significant relative to the background mutation
rate. Indeed, we noted mutations in KRAS, APC and TP53 in five, seven and six
individuals’ tumors, respectively (Supplementary Table 2). We found other genes with
known colorectal cancer mutations, such as NRAS, SMAD4, PIK3CA and FBXW7, to be
mutated here, but these genes’ rates of mutation did not reach statistical significance given
the small sample set. Large sequencing projects will be needed to identify a fuller set of
genes with significant recurrent mutations; such projects are now being carried out under
The Cancer Genome Atlas (see URLs).
Whole-genome sequencing enables detailed study of the nature of chromosomal
rearrangements. Using our algorithm (dRanger10,11), we identified 675 candidate somatic
rearrangements across the nine tumors (mean, 75; range 5–182; Fig. 1 and Supplementary
Table 4) by identifying instances where multiple paired reads map to distinct genomic loci
or with incorrect orientations. To assess the accuracy of these findings, we tested 331
candidate somatic rearrangements by performing PCR across the putative junction in tumor
and germline DNA; we pooled the PCR products and pyrosequenced them. We confirmed
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92% of the calls as true somatic rearrangements; we found four calls (~1%) to be germline
rearrangements and removed them from further analysis, and the remaining 22 calls (~7%)
failed to yield PCR products in either tumor or germline DNA. Tumors with more somatic
coding mutations also harbored more rearrangements (R2 = 0.55).
The majority (82%) of predicted rearrangements are intrachromosomal, and among these
events, roughly half (46%) involve ‘long-range’ events connecting chromosomal regions
more than 1 Mb apart. We classified the short-range rearrangements, occurring at sub-Mb
scales, as deletions (64%), tandem duplications (19%) and inversions (17%) based on an
analysis of the paired-end sequences (Supplementary Fig. 1). We studied the sequence at the
breakpoints in these rearrangements using pyrosequencing of PCR products spanning the
junctions and also using identification in our sequencing of fusion sequences joining
predicted rearrangements using the BreakPointer tool10. The junctions typically show
significant microhomology of 1–6 bases and insertion of non-template DNA is uncommon
(Supplementary Fig. 1), observations that are consistent with results reported in breast
cancer15. Also consistent with prior reports, tandem duplications show a greater degree of
microhomology15.
Three samples (CRC-3, CRC-4 and CRC-6) showed clustering of inter-chromosomal
translocations, where a series of rearrangements leads to extensive regional shuffling of two
to three distinct chromosomes through balanced translocations (Fig. 1). We saw networks of
fusions between chromosomes 8 and 20 in CRC-4 and chromosomes 5 and 11 in CRC-6
(Fig. 2). Because most of these events do not involve regions of substantial copy-number
alterations, they represent a variant of a pattern (termed chromothripsis16) involving
alternating copy-number states induced by a single catastrophic complex genomic event.
Our results show the potential for complex structural alterations to occur in regions of the
genome that appear to be ‘quiet’ based on copy-number profiling.
We examined the specific genes affected by the genomic rearrangements. We found small
deletions in well-known cancer-related genes, including a deletion that removed the first
exon of EGFR in CRC-9 and a deletion removing the 3′ section of PTEN in CRC-8.
Twenty-six genes harbored breakpoints in multiple samples. The most frequently rearranged
genes were MACROD2, A2BP1, FHIT and IMMP2L (Supplementary Table 3), which span
large genomic loci. Previous work has shown that such genes are frequently subject to focal
deletions in cancer17,18, possibly because of structural fragility. Notably, two samples,
CRC-5 and CRC-7, contain chromosome 3:12 translocations in which distinct intergenic
regions of chromosome 3 are fused to the first intron of the methyltransferase-encoding
PRMT8. However, we identified no detectable PRMT8 transcript in RNA from either of the
two samples (data not shown).
We next sought to identify functional fusion genes. Such events have been previously seen
in carcinomas from the lung19 and prostate20, among others, but to our knowledge have not
been reported in colon carcinomas. We found 11 rearrangements (2 interchromosomal and 9
intrachromosomal rearrangements) that could give rise to in-frame fusion transcripts (Table
2). By screening complementary DNA (cDNA) from a panel of 97 primary colorectal
cancers, we found that one of these possible fusion transcripts is recurrently expressed. The
initial observation, which occurred in CRC-9, involved an intrachromosomal fusion on
chromosome 10, fusing the first three exons of VTI1A, which encodes a v-SNARE protein
mediating fusion of intracellular vesicles within the Golgi complex21, to the fourth exon of
the adjacent gene, TCF7L2 (Fig. 3a–c). We found in-frame VTI1A-TCF7L2 fusions in two
additional cases and three of 97 total primary colorectal carcinomas (including the CRC-9
index case) (Supplementary Fig. 2).
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The discovery of recurrent VTI1A-TCF7L2 fusions is of particular interest. TCF7L2
encodes a transcription factor, known as TCF4 and belonging to the TCF/LEF family, that
dimerizes with β-catenin (encoded by CTNNB1) to activate and repress transcription of
genes essential for proliferation and differentiation of intestinal epithelial cells22. TCF7L2 is
the most widely expressed member of the TCF/LEF family in colorectal cancer23 and its
expression is inversely associated with survival in colorectal cancer24. Moreover, the
inherited risk of colorectal cancer is affected by polymorphisms in TCF7L2 (refs. 25,26) as
well as by a polymorphism in an enhancer of MYC at which TCF4 and β-catenin
cooperatively bind27,28. Notably, TCF7L2 is known to harbor somatic point mutations in
colorectal cancer2,3. We additionally found a point mutation in CRC-5 affecting the splice-
site at the 3′ end of exon 10, which is the exon encoding the HMG-box DNA binding
domain, that would likely be a deleterious mutation.
To test the functional importance of the VTI1A-TCF7L2 fusion, we sought a cell line
harboring this event. Because the fusion in CRC-9 is caused by a ~540-kb deletion between
VTI1A and TCF7L2, we studied SNP array data from 38 colorectal cancer cell lines to
search for a similar deletion. We found that the cell line NCI-H508 (Supplementary Fig. 2)
carries such a deletion, and we showed the presence of an in-frame fusion transcript linking
exon 2 of VTI1A to exon 5 of TCF7L2. We designed RNA-interference vectors targeting
the sequence spanning the fusion. Two vectors that reduced the expression of the fusion
mRNA by >70% as gauged by quantitative RT-PCR caused a dramatic reduction in the
anchorage-independent growth of cells from NCI-H508 but not DLD-1, a colorectal cancer
cell line that does not harbor the fusion gene (Fig. 3d,e). This result shows that the VTI1A-
TCF7L2 fusion plays a critical role in NCI-H508 cell growth.
The biochemical function of the VTI1A-TCF7L2 fusion protein is unclear. The fusion omits
the amino-terminal domain of TCF4, which binds β-catenin (Fig. 3c). For other members of
the TCF/LEF family (but not for TCF7L2), isoforms omitting the amino-terminal domain
occur naturally and yield dominant-negative proteins29. However, we do not expect the
VTI1A-TCF7L2 fusion protein to act as a full dominant-negative protein because
engineered dominant-negative TCF4 alleles have been shown to strongly inhibit
proliferation of colorectal carcinoma cell lines30. Given the omission of the β-catenin
binding domain in this fusion gene, we initially hypothesized that this newly identified
protein could enable β-catenin–independent activation of TCF4 and/or β-catenin targets.
However, the three tumors harboring the fusion protein also carry mutations in APC, whose
product suppresses β-catenin. (CRC-9 has one frameshift and one nonsense mutation in
APC, the second tumor harbors a homozygous ~90-kb deletion within APC, and the third
tumor has a p.Ala1247Val APC alteration). NCI-H508 is heterozygous for APC (carrying a
hemizygous deletion) and carries normal alleles at CTNNB1, which encodes β-catenin, yet
is functionally dependent upon β-catenin (Supplementary Fig. 2).
These results suggest that VTI1A-TCF7L2 is expressed in the setting of activated β-catenin
and that NCI-H508 is dependent on both the fusion gene and β-catenin despite the deletion
of the VTI1A-TCF7L2 β-catenin binding domain. Studies will be needed to determine
whether and how (i) the fusion gene interacts or interferes with the function of β-catenin and
(ii) the addition of a section of an N-terminal SNARE domain affects function or
localization. When coupled to the recent report of TCF7L2 mutations in colorectal cancer
and evidence that TCF4 can also have tumor suppressive functions in colorectal
neoplasia31,32, these data suggest additional complexity regarding the function of β-catenin
and its cooperating factors in colorectal cancer.
This report describes the first whole-genome sequencing study of colorectal cancer. Our
results provide no evidence for high-frequency recurrent translocations, such as those that
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are seen in prostate adenocarcinoma20. However, the discovery of the recurrent VTI1A-
TCF7L2 fusion in 3% of colorectal cancers shows that functionally important fusion events
occur in this disease and suggest that further structural characterization will likely identify
additional new recurrent rearrangements.
ONLINE METHODS
Sample selection and preparation
Colorectal adenocarcinoma and matched adjacent non-cancerous colon from affected
individuals not previously treated with chemotherapy or radiation were collected and frozen
at the time of surgery under institutional review board–approved protocols (each collection
was approved by the local institutional review board of the center where surgery was
performed. Subsequently, the Broad Institute’s institutional review board reviewed the local
institutional review board approvals and consent documents to approve the use of samples
for sequencing see Supplementary Note). Tumors were reviewed to confirm the diagnosis
and to estimate tumor content. Nine tumors with an estimated tumor content of at least 70%
were selected. DNA was extracted using standard techniques.
Tumor DNA samples were processed and hybridized to Affymetrix SNP arrays for copy
number analysis. Six of the samples had been evaluated using the STY I array34. The
remaining tumors were evaluated with SNP6 arrays. Array data were processed and
segmented using standard approaches to identify copy number aberrations35. SNP array data
were further analyzed using the tool ABSOLUTE (S.L. Carter, M. Meyerson & G. Getz,
personal communication) to infer the tumor purity and ploidy10,11. Tumors were required to
have either an estimated purity of 50% or an allelic ratio of 0.25.
Whole-genome sequencing
Sequencing was performed using Illumina GA-II10. Briefly, 1–3 micrograms of DNA from
each sample were used to prepare the sequencing library through shearing of the DNA
followed by ligation of sequencing adaptors. Each sample was sequenced on multiple
Illumina flow cells with paired 101-bp reads to achieve ~30× genomic coverage.
Sequence data processing
Raw data were processed using the ‘Picard’ pipeline, which was developed at the Broad
Institute9. As described previously10,11, the BAM file for each tumor and germline sample
(hg18) were generated and imported into the Firehose analysis pipeline11. This system has
been designed to house input files containing sequence data and then organize the execution
of multiple analytic tools to identify somatic aberrations. Copy-number analysis of sequence
data was performed as described previously using whole-genome sequencing data36.
Calculation of sequence coverage, mutation calling and significance analysis
We compared the concordance of sequencing calls and SNP genotypes, which is one metric
of sequencing coverage for mutation detection37. From the Affymetrix data in tumors, we
extracted the high-confidence heterozygous genotype calls and compared these to the
genotypes extracted from the Illumina data. We identified concordance rates of 94–99% in
the tumors and 97–99% in the matched germline DNA samples. We further evaluated the
fraction of all bases suitable for mutation calling whereby a base is defined as covered if at
least 14 and 8 reads overlapped the base in the tumor and in the germline sequencing,
respectively. Those covered regions were subsequently evaluated for single nucleotide
variations using MuTect9–11. Passing single nucleotide variants found within coding areas of
the genome were annotated for their predicted effect on the amino acid sequence and on
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exon splicing. Coding areas were evaluated for insertion-deletion events using the
Indelocator algorithm10,11.
From the candidate somatic mutations and insertions-deletions, predicted non-synonymous
coding alterations were validated in both tumor and matched germline DNA using
multiplexed mass spectrometric genotyping10,35. Among 712 total candidates, genotyping
assays could be designed against and yielded interpretable data for a subset (521
candidates), producing a validation rate of 84%. Notably, all assays from CRC-5 failed in
PCR because of degradation of the DNA from this tumor occurring after Illumina library
construction and sequencing; these assays were removed from evaluation of the validation
rates. Candidate mutations identified in the non-tumor DNA were considered to be germline
polymorphisms and were removed from analysis. Given the possibility for false negative
results from our validation experiments (in particular, the known lack of sensitivity of
multiplexed mass spectrometric genotyping in the case of mutations present at low allele
fraction), to maximize the potential for discovery of new events, we included in our analysis
all 699 mutations not invalidated as germline. As shown in Supplementary Table 1,
mutations are annotated as to those that were tested and validated, tested and not validated
and those not tested because of assay failure.
After all coding single nucleotide variants and insertion-deletions were identified, the
MutSig algorithm was used to identify genes subject to recurrent non-synonymous genetic
alterations at a rate above that which would be expected by chance10,11. The calculated
likelihood for a certain number of mutations to occur by chance takes into account the base
context of the mutations and the rates of those events in the set of genomes. A false
discovery rate (or q value) of 0.05 was used as the cutoff to define significance. All mutation
rates are calculated relative to the theoretical underlying haploid genome.
Identification of rearrangements
The dRanger algorithm10,11 was used to identify genomic rearrangements by identifying
instances where the two read pairs map to distinct regions or map in such a manner that
suggests another structural event, such as an inversion. All such candidate lesions were then
queried in both the matched germline genome and a panel of non-tumor genomes to remove
events detected in germline genomes. The final scorings of these somatic reads were then
calculated by multiplying the number of supporting read pairs by the estimated ‘quality’ of
the candidate rearrangement, a measure ranging from 0 to 1 that takes into account the
alignability of the two regions joined by the putative rearrangement and also the chance of
seeing such a read pair given the libraries’ fragment-size distributions. Those events with
resulting scores ≥3 (and thus seen in at least three read pairs) were included in this analysis.
Validation of rearrangements was performed by PCR using primers spanning the predicted
breakpoints as described previously10. PCR products were sequenced on the 454
pyrosequencing platform with DNA from tumor and matched normal samples to validate the
presence and somatic status of candidate events. For those events failing validation in the
first set of PCRs, a follow-up round of PCR and pyrosequencing was performed with two
sets of primers per candidate rearrangement.
To identify the DNA sequence of the actual fusion between two genomic loci, the
BreakPointer algorithm was employed. BreakPointer searches for read pairs where one read
is mapped entirely on one side of the breakpoint and the pair mate is partly mapped on the
breakpoint or failed to align anywhere. It is expected that many of these reads span the
actual fusion point. These unmapped reads are subjected to a modified Smith-Waterman
alignment procedure with the ability to jump between the two reference sequences at the
most fitting point (Drier, Y. et al., manuscript in preparation). From these breakpoints, the
degree of base overlap or microhomology of the two adjoined sequences was calculated, and
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insertions of non-template DNA were identified. BreakPointer analysis of the Illumina data
was able to predict fusion sites of 214 rearrangements, of which 200 (93.5%) were validated
by pyrosequencing data.
Validation of the VTI1A-TCF7L2 fusion transcript
The NCI-H508 cell line was identified from SNP-array–derived copy number from a
collection of 38 colorectal cancer cell lines in the Broad-Novartis Cell Line Encyclopedia.
RNA prepared from samples of fresh-frozen colorectal adenocarcinomas or, in the case of
the NCI-H508 cell line, a fresh cell pellet, were used for cDNA synthesis with the QIAGEN
QuantiTect kit. cDNA quality was assessed by the ability to PCR amplify the GAPDH
transcript. Passing cDNA was evaluated with a first round of PCR using primers to the 5′
untranslated region of VTI1A and exon 6 of TCF7L2 and then nested PCR using primers
from the first exon of VTI1A and exon 5 of TCF7L2 (the primers used are listed in
Supplementary Table 5). Bands were gel purified, cloned (TOPO TA Cloning; Invitrogen)
and sequenced to validate the presence and frame of fusion.
RNA-interference experiments
Using the sequence of the junction between exon 2 of VTI1A and exon 5 of TCF7L2 from
the NCI-H508 cell line, shRNA vectors containing 21-base seed sequences uniquely
homologous to the fusion sequence were generated and cloned into the pLKO lentiviral
vector38. From these vectors and a control shRNA vector targeting GFP, the lentivirus was
produced and used to infect the NCI-508 cell lines39. Following puromycin selection, RNA
was extracted for cDNA synthesis. Real-time PCR (using two distinct primer sets
quantifying the VTI1A-TCF7L2 fusion; Supplementary Table 5) was used to quantitate the
expression of VTI1A-TCF7L2 mRNA relative to expression of a GAPDH control. Two
shRNAs, which were able to induce significant (~70%) knockdown, were selected for
further experiments. These vectors are labeled shFusionA (target
GAAGCGAAAGAACTGTCTAAC) and shFusionB (target
GCGAAAGAACTGTCTAACAAA). Following new infections of these viruses and shGFP
into NCI-H508 and DLD-1 cell lines, both cultured in Roswell Park Memorial Institute
medium (RPMI) with 10% FBS with glutamine and penicillin streptomycin, cells were
selected with puromycin and then plated into soft agar as previously described to evaluate
anchorage-independent growth39.
For knockdown of CTNNB1 in the NCI-H508 cells, two CTNNB1 shRNA constructs that
had been closed into a doxycline-inducible version of the pLKO.1 vector were used. The
two vectors contained sequencing targeting the following sites: sh35:
CCCTAGCCTTGCTTGTTAAAA and sh36: GGACAAGCCACAAGATTACAA, with
knockdown verified by real-time PCR (Applied Bisosystems Hs00170025_m1). Cells
infected with NTC (non-targeting control) or CTNNB1 shRNA were grown in the presence
or absence of 20 ng/ml doxycycline for 48 h. To quantitate knockdown, RNA from shRNA-
infected cells was quantified with real-time PCR. Cells were then placed into soft agar in the
presence or absence of 20 ng/ml doxycycline to assess colony formation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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DNA structural rearrangements and copy number alterations detected in the nine colorectal
tumors displayed as CIRCOS plots33. Chromosomes are arranged circularly end-to-end with
each chromosome’s cytobands marked in the outer ring. The inner ring displays copy
number data inferred from whole-genome sequencing with blue indicating losses and red
indicating gains. Within the circle, rearrangements are shown as arcs with intrachromosomal
events in green and interchromosomal translocations in purple.
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Complex rearrangements between chromosome pairs in two colorectal carcinomas. The
central portion of the figure contains copy-number profiles across all chromosomes with the
chromosome identity labeled across the x axis and the scale for copy-number ratio (log2)
depicted on the y axis of each plot. The upper plot shows the tumor CRC-4, and the lower
plot shows the copy-number profile for CRC-6, with the black dots marking the copy-
number ratio inferred along each locus across the genome. The upper inset boxes show
detailed views of the copy numbers and rearrangements for chromosomes 8 (dark blue) and
20 (ochre) for CRC-4 with the centromere labeled as a purple circle. Rearrangements
detected by dRanger are shown in green (intrachromosomal) and purple (interchromosomal).
The lower inset boxes show detailed copy-number and rearrangement images for CRC-6,
with inset boxes showing chromosome 5 (red) and 11 (gray), with lines marking positions of
genomic rearrangements.
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Recurrent gene fusion between VTI1A and TCF7L2. (a) The upper schematic depicts the
positions of exons (vertical lines) within VTI1A and TCF7L2, which reside adjacent to each
other on chromosome 10. The blowup displays the locations of discordant paired-end reads
found in tumor CRC-9 for which one read (labeled in blue) is in an intron of VTI1A and the
other read (labeled in red) is in an intron of TCF7L2. (b) The upper schematic depicts the
structure of the predicted fusion transcript generated by the fusion. The presence of the exact
reads spanning the fusion of the two introns (marked by lightning bolt) is depicted in the
inset with regions of the reads corresponding to original VTI1A intron in blue and those of
TCF7L2 in red. (c) The protein domain structure of native VTI1A and TCF4-TCF7L2,
including the two alternate C-terminal tails of TCF4, are shown. Below are the structures of
the fusion protein encoded by the fusion of exon 3 of VTI1A to exon 4 of TCF7L2 identified
in CRC-9. Two variants of the fusion are shown as data from the NCI-H508 cell line and
reveal that variants encoding both the full length (E-tail) and shorter (B-tail) C termini are
both expressed (data not shown). (d) Measurement of the relative expression of the VTI1A-
TCF7L2 mRNA in NCI-H508 cells infected with one of two short hairpin RNA constructs
targeting the fusion gene relative to expression in a cell infected with control vectors
targeting GFP. (e) Anchorage-independent growth of the NCIH508 cell line, which
expresses VTI1A-TCF7L2, and negative control DLD-1 colorectal adenocarcinoma cells
following RNA-interference–mediated knockdown of VTI1A-TCF7L2 compared to control
knockdown targeting GFP.
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Table 2
Predicted in-frame fusion proteins detected by dRanger
Tumor Fusion Fusion Sites
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